The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Big physics, small doses: the use of AMS and PET in human microdosing of development drugs
Open accessAbstract
The process of early clinical drug development has changed little over the past 20 years despite an up to 40% failure rate associated with inappropriate drug metabolism and pharmacokinetics of candidate molecules. A new method of obtaining human metabolism data known as microdosing has been developed which will permit smarter candidate selection by taking investigational drugs into humans earlier. Microdosing depends on the availability of two ultrasensitive 'big-physics' techniques: positron emission tomography (PET) can provide pharmacodynamic information, whereas accelerator mass spectrometry (AMS) provides pharmacokinetic information. Microdosing allows safer human studies as well as reducing the use of animals in preclinical toxicology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integration of virtual and high-throughput screening
Bajorath, J. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd941 · Cited by 930
High-throughput crystallography for lead discovery in drug design
Blundell, T. L., Jhoti, H., & Abell, C. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd706 · Cited by 530
Pharmaceutical innovation by the seven UK‐owned pharmaceutical companies (1964‐1985).
Prentis, R., Lis, Y., & Walker, Sr. (1988) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1988.tb03318.x · Cited by 471
Risks in new drug development: Approval success rates for investigational drugs
DiMasi, J. A. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.115446 · Cited by 450
(1998) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-1998-159 · Cited by 191
Turteltaub, K. W., Felton, J. S., Gledhill, B. L., Vogel, J. S., Southon, J. R., Caffee, M. W., Finkel, R. C., Nelson, D. E., Proctor, I. D., & Davis, J. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.14.5288 · Cited by 188
Fundamentals of Positron Emission Tomography and Applications in Preclinical Drug Development
Cherry, S. R. (2001) · The Journal of Clinical Pharmacology · doi:10.1177/00912700122010357 · Cited by 153
Lesko, L. J., Rowland, M., Peck, C. C., & Blaschke, T. F. (2000) · The Journal of Clinical Pharmacology · doi:10.1177/00912700022009530 · Cited by 152
Testino, S. A., & Patonay, G. (2002) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/s0731-7085(02)00480-6 · Cited by 121
PET for in vivo pharmacokinetic and pharmacodynamic measurements
Gupta, N., Price, P., & Aboagye, E. O. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00413-6 · Cited by 112
Cited by
Weissleder, R. (2006) · Science · doi:10.1126/science.1125949 · Cited by 1,112
HIV drug development: the next 25 years
Flexner, C. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2336 · Cited by 317
Bergstr�m, M., Grahn�n, A., & L�ngstr�m, B. (2003) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-003-0643-x · Cited by 311
Liposome imaging agents in personalized medicine
Petersen, A. L., Hansen, A. E., Gabizon, A., & Andresen, T. L. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.003 · Cited by 164
The Nuremberg Code subverts human health and safety by requiring animal modeling
Greek, R., Pippus, A., & Hansen, L. A. (2012) · BMC Medical Ethics · doi:10.1186/1472-6939-13-16 · Cited by 78
Metadata
- Authors
- Lappin, G., & Garner, R. C.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2003-03
- Volume
- 2
- Issue
- 3
- Pages
- 233-240
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2091711716
- Cited by
- 260
- References
- 20
- FWCI
- 1.07
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Big physics, small doses: the use of AMS and PET in human microdosing of development drugs. https://app.cochat.ai/papers/10.1038/nrd1037
- The paper
- Lappin, G., & Garner, R. C. (2003). Big physics, small doses: the use of AMS and PET in human microdosing of development drugs. Nature Reviews Drug Discovery. https://doi.org/10.1038/nrd1037
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.